2 recruiting, 1 terminated, 1 unknown. 3 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 1, Terminated 1, Unknown 1 |
| Phase 1 | 2 | Recruiting 1, Terminated 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Levo-Leucovorin: new trials by email Literature Review of Levo-Leucovorin trials Research Report on Levo-Leucovorin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma Tislelizumab, Oxaliplatin injection, Levo-Leucovorin - Gastric Cancer | Phase 3 | Recruiting | Fujian Cancer Hospital | 269 | 2025-06-07 | 2025-07-20 |
| Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer Tislelizumab, Oxaliplatin, Levo-Leucovorin - Gastric Cancer | Phase 2 | Unknown | Fujian Cancer Hospital | 36 | 2024-01-01 | 2024-01-09 |
| NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours Fosifloxuridine Nafalbenamide, Leucovorin, Pembrolizumab - Advanced Cancer, Advanced Solid Tumor | Phase 1 / Phase 2 | Terminated | NuCana plc | 19 | 2023-03-08 | 2026-07-23 |
| Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab Oxaliplatin, Levo-Leucovorin, 5-fluorouracil - Gastric Cancer Stage IV | Phase 1 / Phase 2 | Recruiting | Fujian Cancer Hospital | 51 | 2023-02-16 | 2025-02-27 |
Stomach Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Melanoma (1) · Mesothelioma, Malignant (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1) · Triple Negative Breast Neoplasms (1)
Fujian Cancer Hospital (3) · NuCana plc (1)
China (2) · United Kingdom (1)